` HLVX (Hillevax Inc) vs S&P 500 Comparison - Alpha Spread

H
HLVX
vs
S&P 500

Over the past 12 months, HLVX has underperformed S&P 500, delivering a return of +12% compared to the S&P 500's +15% growth.

Stocks Performance
HLVX vs S&P 500

Loading
HLVX
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
HLVX vs S&P 500

Loading
HLVX
S&P 500
Difference
www.alphaspread.com

Performance By Year
HLVX vs S&P 500

Loading
HLVX
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Hillevax Inc vs Peers

S&P 500
HLVX
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Hillevax Inc
Glance View

Market Cap
104.8m USD
Industry
Biotechnology

Hillevax Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Boston, Massachusetts. The company went IPO on 2022-04-29. HilleVax, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines. The firm's program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. Norovirus is the most common cause of viral AGE worldwide and is characterized by symptoms, including diarrhea, vomiting, abdominal pain, nausea, and, sometimes, fever that may lead to clinically significant dehydration. The firm's HIL-214 is a bivalent (containing two proteins) vaccine candidate consisting of VLPs representing two common genotypes of norovirus and is co-formulated with an aluminum hydroxide (alum) adjuvant, which is commonly used in adult and pediatric vaccines to enhance immunogenicity. HIL-214 comprises VLPs for the two major genotypes of norovirus: GI.1 and GII.4. The firm's clinical development plan is focused on infants.

HLVX Intrinsic Value
3.42 USD
Undervaluation 39%
Intrinsic Value
Price
H
Back to Top